Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

June 14th 2024

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

June 10th 2024

Enrollment of patients in a phase 2 study evaluating SLS009 in relapsed/refractory AML has been completed and the agent demonstrated initial efficacy.

SL-172154 Receives FDA Orphan Drug Designation in AML

June 10th 2024

SL-172154 has been granted orphan drug designation from the FDA in acute myeloid leukemia.

China’s NMPA Accepts BLA for Zanidatamab in HER2+ Biliary Tract Cancer

June 10th 2024

China’s National Medical Products Administration has accepted the biologics license application for zanidatamab in second-line HER2+ biliary tract cancer.

Braun Spotlights Novel Treatment Developments in RCC

June 10th 2024

David A. Braun, MD, PhD, highlights the developing role of T-cell therapies in RCC and looks toward the horizon for other advances.

Braun Highlights Advances in RCC Treatment Paradigm, Looks Towards Future

June 7th 2024

David A. Braun, MD, PhD, discusses the evolving treatment landscape of renal cell carcinoma.

New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings

June 6th 2024

The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

June 6th 2024

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC

June 5th 2024

Lenvatinib/pembrolizumab offered a significant benefit in terms of time to disease progression in all organs vs sunitinib in advanced RCC.

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

June 2nd 2024

Perioperative chemotherapy with FLOT improved OS vs neoadjuvant chemoradiation with CROSS in resectable esophageal cancer.

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

May 31st 2024

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation

May 30th 2024

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

AGuIX Receives FDA Fast Track Designation in Glioblastoma

May 30th 2024

AGuIX has been granted FDA fast track designation in malignant gliomas and glioblastoma.

Nivolumab/Cabozantinib Combination Displays Activity in Non-Clear Cell RCC

May 29th 2024

Treatment with nivolumab plus cabozantinib yielded responses in patients with non-clear cell renal cell carcinoma.

CAR T-Cell Therapy Makes its Mark in CLL

May 26th 2024

David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.

Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer

May 24th 2024

Ribociclib plus endocrine therapy bested combination chemotherapy in terms of progression-free survival in HR-positive, HER2-negative advanced breast cancer.

AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices

May 24th 2024

An artificial intelligence-based smartphone app used by primary care physicians showed high diagnostic accuracy in detecting cutaneous melanoma.

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

May 23rd 2024

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Guardant360 CDx Gains European Union Certification for Tumor Profiling in Solid Tumors

May 22nd 2024

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

May 22nd 2024

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.